Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease

Transplantation

Volumn 80, Issue 5, 2005, Pages 634-642

  Robin, Marie ^a   Guardiola, Philippe ^a   Girinsky, Théodore ^b   Hernandez, Gabriella ^a   Espérou, Hélène ^a   Ribaud, Patricia ^a   Rocha, Vanderson ^a   Garnier, Federico ^a   Socié, Gérard ^a   Gluckman, Eliane ^a   Devergie, Agnès ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Extensive chronic GvHD; Immunosuppressive therapy

Indexed keywords

AZATHIOPRINE; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CORTICOSTEROID THERAPY; FASCIITIS; FEMALE; HUMAN; INCIDENCE; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; RADIOTHERAPY; REMISSION; RETROSPECTIVE STUDY; SAFETY; SYSTEMIC DISEASE; THORACOABDOMINAL IRRADIATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ABDOMEN; ADOLESCENT; ADULT; CHILD; CHRONIC DISEASE; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RADIATION DOSAGE; RADIOTHERAPY; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THORAX; TRANSPLANTATION, HOMOLOGOUS;

EID: 25444491999     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000173436.99153.78     Document Type: Article

References (45)

1. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatr Transplant 7 Suppl 2003; 3: 19-31.
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
3. Arora M, Burns LJ, Davies SM, et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003; 9: 38-45
4. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
5. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 167-176.
6. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-771
7. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
8. Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus- malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
9. Goerner M, Gooley T, Flowers ME, et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002; 8: 47-56.
10. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
11. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
12. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 72: 555-561.
13. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546-554.
14. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055-1058.
15. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 495-502.
16. Dall'Amico R, Rossetti F, Zulian F, et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997; 97: 848-854.
17. Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807-811.
18. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098-3104.
19. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517-520.
20. Slavin S. Successful treatment of autoimmune disease in (NZB/ NZW)F1 female mice by using fractionated total lymphoid irradiation. Proc Natl Acad Sci USA 1979; 76: 5274-5276.
21. Strober S, Gottlieb M, Slavin S, et al. Use of total lymphoid irradiation (TLI) in bone marrow and organ transplantation. Transplant Proc 1979; 11: 1930-1933.
22. Valentine VG, Robbins RC, Wehner JH, et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest 1996; 109: 1184-1189.
23. Field EH, Rouse TM, Gao Q, Chang B. Association between enhanced Th2/Th1 cytokine profile and donor T-cell chimerism following total lymphoid irradiation. Hum Immunol 1997; 52: 144-154.
24. Lan F, Zeng D, Higuchi M, et al. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003; 9: 355-363.
25. Gaziev D, Giardini C, Galimberti M, et al. Bone marrow transplantation for transfused patients with severe aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning therapy: long-term follow-up from a single center. Bone Marrow Transplant 1999; 24: 253-257.
26. Ramsay NK, Kim TH, McGlave P, et al. Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia. Blood 1983; 62: 622-626.
27. Gluckman E, Socie G, Devergie A, et al. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood 1991; 78: 2451-2455.
28. Socie G, Devergie A, Cosset JM, et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990; 49: 657-658.
29. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
30. Kaplan ES, P M. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
31. Gray RJ. Spline-based tests in survival analysis. Biometrics 1994; 50: 640-652.
32. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219-1226.
33. Janin A, Socie G, Devergie A, et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med 1994; 120: 993-998.
34. Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 1977; 146: 34-48.
35. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604-3609.
36. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995-3996.
37. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-392.
38. Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102: 1217-1223.
39. Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003; 31: 459-465.
40. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118-127.
41. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74: 1428-1435.
42. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
43. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102: 802-809.
44. Rook AH, Suchin KR, Kao DM, et al. Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc 1999; 4: 85-90.
45. Cox D. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.